From Surf Wiki (app.surf) — the open knowledge base
Roskamp Institute
| Field | Value |
|---|---|
| name | The Roskamp Institute |
| image | Roskamp_Exterior.jpg |
| image_caption | The Roskamp Institute Headquarters in Sarasota, Florida |
| type | Nonprofit |
| industry | Biotechnology |
| founded | |
| founders | |
| hq_location_city | Sarasota, Florida |
| hq_location_country | United States |
| area_served | Worldwide |
| website |
The Roskamp Institute, was co-founded by Robert and Diane Roskamp, and Fiona Crawford and Michael Mullan in Sarasota, Florida in 2003. It is a nonprofit biomedical research facility specializing neurological research including Alzheimer's disease, traumatic brain injury, Gulf War syndrome, and posttraumatic stress disorder. It also operates an onsite neurology clinic. The institute is focused on finding the causes and treatments for neuropsychiatric and neurodegenerative diseases.
The institute's lead researchers, Michael Mullan and Fiona Crawford, were members of a team of scientists who discovered the first genetic errors causing Alzheimer's disease in 1991 in the APP gene in early onset familial cases. Mullan and Crawford also discovered the Swedish mutation which has been incorporated into transgenic mice which are widely used to understand the disease and test new treatments.
The institute is particularly focused on translational research that can lead to novel drug or other therapeutic interventions in neurodegenerative disorders. In this regard, Institute scientists discovered that certain members of a class of drugs called dihydropyridines [DHPs] can lower the levels of amyloid beta in the brains of transgenic models of the disease and decided to take one of them, nilvadipine, forward into clinical trials for Alzheimer's disease. This work was conducted by Archer Pharmaceuticals, a for-profit spin off of the institute, headed by Mullan. In partnership with colleagues at Trinity College, Dublin led by Brian Lawlor, Archer and Institute scientists conducted an open label phase I/II trial of nilvadipine in mild to moderate Alzheimer's disease subjects. More recently, in collaboration with multiple partners at academic institutes in Europe, and again led by Lawlor, Archer and Roskamp Institute scientists partnered to conduct a phase III clinical trial of nilvadipine in mild to moderate Alzheimer's disease.
The institute is currently housed in a 41000 sqft scientific research facility in Sarasota, Florida. The institute facility contains mass spectrometry, pathology, microscopy, certified GMO testing, and chemistry labs. The organization employs more than 50 scientists, technicians, clinicians, and other research staff.
References
References
- (26 January 2007). "Sarasota's Roskamp Institute Discovers New Class Of Drugs That Can Impact Alzheimer's Disease". [[Medical News Today]].
- "Who We Are: Executive Leadership". roskampinstitute.org.
- Mullan, M.. (August 1992). "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid". Nature Genetics.
- Lawlor, Brian. (2014-10-01). "NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease". BMJ Open.
- Dublin, Trinity News and Events, Trinity College. "Clinical Trials for New Alzheimer's Disease Treatment Led by Trinity College Dublin Researchers to be Awarded European Commission 6 million Funding".
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Roskamp Institute — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report